As countries in the Northern hemisphere deal with the flu season, experts say regulation surrounding flu vaccines could be due for a shake up with new healthcare leaders set to take charge in the US.

TYRA-300 is a small molecule commercialized by Tyra Biosciences, with a leading Phase II program in Solid Tumor.

Conduit Pharmaceuticals has signed an agreement with Sarborg to leverage advanced AI and cybernetics for the optimisation of processes related to key drug development. These include the repurposing ...

When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a handful said yes.

BDTX-1535 is a small molecule commercialized by Black Diamond Therapeutics, with a leading Phase II program in Non-Small Cell Lung Cancer.

China’s NMPA has granted approval to Santhera Pharmaceuticals’ AGAMREE, used in treating DMD in individuals aged four years and above.

SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy.

Aflibercept Biosimilar is a fusion protein commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Wet (Neovascular / Exudative) Macular Degeneration.

HS-001 is a cell therapy commercialized by Novo Nordisk, with a leading Phase II program in Systolic Heart Failure.

AIM ImmunoTech has secured a patent from the Netherlands Patent Office for Ampligen, targeting the treatment of post-Covid fatigue.

TPST-1120 is a small molecule commercialized by Tempest Therapeutics, with a leading Phase II program in Metastatic Hepatocellular Carcinoma (HCC).